医学
荟萃分析
科克伦图书馆
置信区间
子群分析
围手术期
冲程(发动机)
主动脉修补术
内科学
外科
急性肾损伤
死亡率
心脏病学
主动脉
机械工程
工程类
作者
Heyue Jia,Pengfei Yuan,Shanshan Wu,Rui Yang,Hai‐Lei Li,Wei Guo,Duanduan Chen,Jiang Xiong
标识
DOI:10.1016/j.avsg.2023.12.087
摘要
Abstract
Objective
To assess the mortality and outcomes following thoracic endovascular aortic repair (TEVAR) in patients with type B aortic dissection (TBAD) in mainland China, and to compare these outcomes with data from Western countries, while analyzing the potential reasons for differences among different countries. Methods
An extensive literature search spanning from January 1999 to October 2023 was conducted using PubMed, Cochrane Library, and Embase databases for studies on endovascular treatment for TBAD. This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Data extraction and analysis followed the guidelines outlined in the PRISMA statement. Primary outcomes were in-hospital mortality and mid-term (<5 years) mortality. Results
Based on 25 publications (3080 patients), pooled estimate for in-hospital mortality was 2.2% [95% CI, 1.6%-2.9%]. Major perioperative complications included stroke (2.4% [1.8%-3.3%]), spinal cord ischemia (1.4% [1.0%-2.2%]), retrograde type A aortic dissection (1.2% [0.8%-1.8%]), type I endoleak (5.6% [3.6%-8.6%]), visceral ischemia (1.0% [0.5%-2.1%]) and acute renal failure (2.8% [2.0%-3.8%]). Mid-term mortality was 5.1% [3.6%-7.3%], and secondary intervention rate was 4.9% [4.0%-6.0%] with 1.7% [1.0%-2.9%] conversion rate to open surgery. In subgroup analysis based on uncomplicated TBAD, in-hospital and mid-term mortality was 0.5% [0.2%-1.5%] and 0.6% [0.2-1.7%], respectively. Compared with data from Western countries, mainland Chinese patients had a lower mortality. Conclusion
In mainland China, the outcomes of endovascular treatment for TBAD are comparable to those of Western countries. The large number of patients undergoing TEVAR in mainland China, and its good performance support the use of TEVAR in uncomplicated TBAD.
科研通智能强力驱动
Strongly Powered by AbleSci AI